Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

J. Joyner, Michael; E. Carter, Rickey; W. Senefeld, Jonathon; A. Klassen, Stephen; R. Mills, John; W. Johnson, Patrick; S. Theel, Elitza; C. Wiggins, Chad; A. Bruno, Katelyn; M. Klompas, Allan; R. Lesser, Elizabeth; L. Kunze, Katie; A. Sexton, Matthew; C. Diaz Soto, Juan; E. Baker, Sarah; R.A. Shepherd, John; van Helmond, Noud; Verdun, Nicole; Marks, Peter; M. van Buskirk, Camille; L. Winters, Jeffrey; R. Stubbs, James; F. Rea, Robert; O. Hodge, David; Herasevich, Vitaly; R. Whelan, Emily; J. Clayburn, Andrew; F. Larson, Kathryn; G. Ripoll, Juan; J. Andersen, Kylie; Buras, Matthew; N.P. Vogt, Matthew; J. Dennis, Joshua; J. Regimbal, Riley; R. Bauer, Philippe; E. Blair, Janis; Paneth, Nigel; Fairweather, DeLisa; Scott Wright, R.; Casadevall, Arturo

doi:10.1056/nejmoa2031893

Public

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Published in New England Journal of Medicine • Jan 13, 2021

Authors:

Michael J. Joyner

Rickey E. Carter

Jonathon W. Senefeld

Abstract

BACKGROUND: Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be passively transferred to the plasma recipie...

Subject

Convalescent plasma

Coronavirus disease 2019 (COVID-19)

Virology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!